Aclaris Therapeutics Company Profile (NASDAQ:ACRS)

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.68) by $0.12. View Aclaris Therapeutics' Earnings History.

Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Aclaris Therapeutics.

5 equities research analysts have issued 12-month target prices for Aclaris Therapeutics' stock. Their predictions range from $34.00 to $50.00. On average, they anticipate Aclaris Therapeutics' stock price to reach $40.00 in the next twelve months. View Analyst Ratings for Aclaris Therapeutics.

Here are some recent quotes from research analysts about Aclaris Therapeutics stock:

• 1. According to Zacks Investment Research, "Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. " (5/12/2017)
• 2. Jefferies Group LLC analysts commented, "ACRS reported a narrower Q4 loss of $11.5M (vs $14.5M JEF) due to lower than projected R&D spend post the SK Ph3 trials. Attention now turns to three new clinical trials (A-101 Phase 2b in common warts and two JAK Ph 2s in alopecia areata) as we wait for an FDA decision on A-101 in SKs in early '18. We continue to forecast peak sales approaching $500M for the drug/device combo and think ACRS fits our M&A thesis." (3/16/2017)
• 3. Guggenheim analysts commented, "We are raising our PT from $35 to $40 post 4Q16. We arrive at our PT by using a DCF analysis. Post the quarter, we continue to believe that upwards earnings revisions to levels not yet reflected in sell-side expectations should drive ACRS shares higher. We believe upwards consensus earnings revisions could come from: 1) Faster than expected uptake and higher than expected peak sales of A-101 for SK; 2) Commercialization of A-101 for common warts; and, 3) Free call options on ATI-50001, ATI-50002, and other early stage pipeline opportunities." (3/15/2017)

Some companies that are related to Aclaris Therapeutics include Acceleron Pharma (XLRN), MyoKardia (MYOK), Clinigen Group PLC (CLIN), Forward Pharma A/S (FWP), Omeros Corporation (OMER), Acorda Therapeutics (ACOR), NeuroDerm (NDRM), Dynavax Technologies Corporation (DVAX), Dermira (DERM), Xencor (XNCR), Retrophin (RTRX), Ascendis Pharma A/S (ASND), Sangamo Therapeutics (SGMO), Amarin Corporation PLC (AMRN), Epizyme (EPZM), Five Prime Therapeutics (FPRX), Aduro Biotech (ADRO) and Keryx Biopharmaceuticals (KERX).

Aclaris Therapeutics' management team includes the folowing people:

• Stephen A. Tullman, Chairman of the Board
• Neal Walker, President, Chief Executive Officer, Director
• Frank Ruffo CPA, Chief Financial Officer, Secretary
• Christopher Powala, Chief Operating Officer
• Stuart D. Shanler M.D., Chief Scientific Officer
• Kamil Ali-Jackson J.D., Chief Legal Officer
• Richard A. Bierly, Independent Director
• William D. Humphries, Independent Director
• Anand Mehra M.D., Independent Director
• Andrew Kenneth William Powell, Independent Director

Aclaris Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (10.69%), Franklin Resources Inc. (7.31%), FMR LLC (7.09%), Sofinnova Management VIII L.L.C. (5.76%), Eagle Asset Management Inc. (5.08%) and Westfield Capital Management Co. LP (4.67%). Company insiders that own Aclaris Therapeutics stock include Albert Cha, Anand Mehra, Andrew N Schiff, Fmr Llc, Kamil Ali-Jackson, Ra Capital Management, Llc, Sofinnova Venture Partners Vii, Ventures Fund Vii LP Vivo and Vivo Ventures Vii, Llc. View Institutional Ownership Trends for Aclaris Therapeutics.

Aclaris Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, PointState Capital LP, Parametric Portfolio Associates LLC, Citadel Advisors LLC, Capital Impact Advisors LLC, Caxton Corp, Russell Investments Group Ltd. and Rothschild Asset Management Inc.. Company insiders that have sold Aclaris Therapeutics stock in the last year include Anand Mehra, Kamil Ali-Jackson, Ra Capital Management, Llc and Ventures Fund Vii LP Vivo. View Insider Buying and Selling for Aclaris Therapeutics.

Aclaris Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Franklin Resources Inc., Westfield Capital Management Co. LP, FMR LLC, Nexthera Capital LP, Marshall Wace North America L.P., State Street Corp and UBS Asset Management Americas Inc.. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Albert Cha, Andrew N Schiff, Fmr Llc, Ra Capital Management, Llc, Sofinnova Venture Partners Vii and Vivo Ventures Vii, Llc. View Insider Buying and Selling for Aclaris Therapeutics.

Shares of Aclaris Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Aclaris Therapeutics stock can currently be purchased for approximately $24.96.